Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study

Next Previous
Trial Profile

Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acoziborole (Primary)
  • Indications African trypanosomiasis
  • Focus Therapeutic Use
  • Acronyms OXA002

Most Recent Events

  • 17 Sep 2025 Number of treatment arms increased from 1 to 2 by the addition of Experimental: Early- and intermediate-stage HAT arm. Study design changed from single group assignment to parallel.
  • 17 Sep 2025 Actual primary completion date changed from 28 Aug 2020 to 8 Sep 2020.
  • 17 Jan 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top